• DOI:10.1002/j.1875-9114.1998.tb03880.x
Corpus ID: 44496161

Economic Considerations in Alzheimer's Disease

@article{Meek1998EconomicCI,
  title={Economic Considerations in Alzheimer's Disease},
  author={P. Meek and E. McKeithan and G. Schumock},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={1998},
  volume={18}
}

• P. Meek, E. McKeithan, G. Schumock
• Published 1998
• Medicine
• Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Alzheimer's disease (AD) is the third most expensive disease in the United States, costing society approximately $100 billion each year. It is one of the most prevalent illnesses in the elderly population, and with the aging of society, will become even more significant. Costs associated with AD include direct medical costs such as nursing home care, direct nonmedical costs such as in‐home day care, and indirect costs such as lost patient and caregiver productivity. Medical treatment may have… Expand

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed